Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022
Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases,...
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition
BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for...
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology...
Yuyu Pharma attendance at European Pharmaceutical Conference
SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma, has been attending biopharmaceutical conferences held in Germany, BIO-Europe and CPHI. The purpose is to explore opportunities to expand into international markets, such as Europe. Robert Yu, CEO of Yuyu Pharma, has been attending biopharmaceutical conferences held in Germany, BIO-Europe and...
2nd Global Forum of People’s Organizations on Hansen’s Disease Focuses on Capacity Building to Promote Dignity of Those Affected by the Disease
TOKYO, Nov. 3, 2022 /PRNewswire/ -- The 2nd Global Forum of People's Organizations on Hansen's Disease takes place in Hyderabad, India, from November 6 to 8, 2022. Organized by Sasakawa Leprosy (Hansen's Disease) Initiative as part of its "Don't Forget Leprosy" campaign, the forum is being held ahead of the 21st International Leprosy Congress (ILC), which brings together the key...
Zhongchao Inc.’s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market
SHANGHAI, Nov. 3, 2022 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, Chongqing Xinjiang Pharmaceutical Co., Ltd. ("Xinjiang Pharmaceutical") has...
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"),...
Merck KGaA, Darmstadt, Germany and p-Chip Corporation Collaborate to Improve Trust and Transparency in Machine-to-Machine Driven Industrial Value Chains
CHICAGO, Nov. 3, 2022 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and p-Chip Corporation, a company that is revolutionizing the tracking of physical products and materials with its breakthrough microtransponder technology, today announced the conclusion of a joint development agreement to develop and implement a new solution that offers never-before-seen levels of digital trust...
Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004
BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004 for type 2 diabetes mellitus (T2DM). This study will evaluate the safety,...
Docquity digitized patient affordability programs in the Philippines, saving over US$1M for patients
More than 350 doctors have supported over 1,000 cancer patients to get improved and affordable care since the start of the pilot last year MANILA, Philippines, Nov. 3, 2022 /PRNewswire/ -- In support of the Philippine government's initiatives to promote universal healthcare, Docquity, Southeast Asia's largest trusted community of healthcare professionals, is...
